These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27166975)

  • 41. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
    Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Srinivasan S; Kaur V; Chamarthi B; Littleton KR; Chen L; Manning AK; Merino J; Thomas MK; Hudson M; Goldfine A; Florez JC
    Diabetes Care; 2018 Mar; 41(3):554-561. PubMed ID: 29326107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular effects of incretins in diabetes.
    Advani A; Bugyei-Twum A; Connelly KA
    Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incretin physiology and its role in type 2 diabetes mellitus.
    Svec F
    J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New prospects for incretin-related drugs in the treatment of type 2 diabetes.
    Kimura T; Kaku K
    J Diabetes Investig; 2021 Jul; 12(7):1141-1143. PubMed ID: 33151639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor.
    Kodera R; Shikata K
    J Diabetes Investig; 2016 Jan; 7(1):29-31. PubMed ID: 26816598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 54. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N; Sriwijitkamol A
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The physiology of incretins].
    Winkler G
    Orv Hetil; 2011 Nov; 152(48):1922-30. PubMed ID: 22167829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gliptins: a new class of oral hypoglycaemic agent.
    Chahal H; Chowdhury TA
    QJM; 2007 Nov; 100(11):671-7. PubMed ID: 17881415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.
    Han E; Park HS; Kwon O; Choe EY; Wang HJ; Lee YH; Lee SH; Kim CH; Kim LK; Kwak SH; Park KS; Kim CS; Kang ES
    Medicine (Baltimore); 2016 Nov; 95(44):e5155. PubMed ID: 27858848
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1.
    Smushkin G; Sathananthan M; Sathananthan A; Dalla Man C; Micheletto F; Zinsmeister AR; Cobelli C; Vella A
    Diabetes; 2012 May; 61(5):1082-9. PubMed ID: 22461567
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cardiovascular Effects of Incretin-Based Therapies and Their Therapeutic Potential].
    Tyurenkov IN; Bakulin DA; Kurkin DV; Volotova EV
    Vestn Ross Akad Med Nauk; 2017; 72(1):66-75. PubMed ID: 29308856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.